Annie Curtis

So these are things like, you know, mRNA that are in there.

It's like a little envelope that goes out and kind of signals to other cells.

So we figured out that that's one of the reasons that we're working.

But the big discovery that we had is that we could create a better macrophage to do this.

And how we did it was we kind of tinkered with the cell's metabolism.

So metabolism is basically all the reactions that happen within a cell to make it viable.

And we tinkered with that metabolism and we were able to create, and I love this, a hybrid macrophage, which is a combination of M1 and M2.

And what we found with those macrophages, again, how they signaled was little pockets of information.

But we could basically generate more vessels in the bone because you need vessels in the bone to kind of bring, you know, blood and oxygen and whatever.

And then also we found that it was better at making bones.

So we were able to kind of generate a new macrophage.

No, no.

What we did was we put in a drug that we knew tinkered with the metabolism.

And we had kind of an idea that it might do that just in terms of the chemical reactions that it was going to kind of hit.

And that's how we created this.

So look, it's still early days.

You know, there's a lot more work to be done in the lab before we can see this in kind of a preclinic or clinical concept.

But it's probably just the concept of it that making these hybrid macrophages could be really good for bone regeneration.

Absolutely.

For any fracture, yeah, we could use that.